Antisense oligonucleotides: is the glass half full or half empty? - PubMed (original) (raw)
Review
Antisense oligonucleotides: is the glass half full or half empty?
C F Bennett. Biochem Pharmacol. 1998.
Abstract
Antisense oligonucleotides are widely used as tools to explore the pharmacological effects of inhibiting expression of a selected gene product. In addition, they are being investigated as therapeutic agents for the treatment of viral infections, cancers, and inflammatory disorders. Proof that the pharmacological effects produced by the oligonucleotides are attributable to an antisense mechanism of action requires careful experimentation. Central to this problem is the finding that oligonucleotides are capable of interacting with and modulating function of specific proteins in both a sequence-independent and -dependent manner. Despite these undesired interactions, it has been possible to demonstrate that oligonucleotides are capable of binding to a specific RNA in cultured cells, or within tissues, resulting in selective reduction of the targeted gene product and pharmacological activity. In general, these oligonucleotides were identified after a selection process in which multiple oligonucleotides targeting different regions on the RNA were evaluated for direct inhibition of targeted gene product, resulting in the identification of a potent and selective oligonucleotide. Similar to other drug-receptor interactions, selection of the most potent inhibitor results in an increase in the signal-to-noise ratio, yielding increased confidence that activity observed is the result of a desired effect of the inhibitor. With careful selection, proper controls, and careful dose-response curves it is possible to utilize antisense oligonucleotides as effective research tools and potentially as therapeutic agents.
Similar articles
- Progress in antisense oligonucleotide therapeutics.
Crooke ST, Bennett CF. Crooke ST, et al. Annu Rev Pharmacol Toxicol. 1996;36:107-29. doi: 10.1146/annurev.pa.36.040196.000543. Annu Rev Pharmacol Toxicol. 1996. PMID: 8725384 Review. - RNA mapping: selection of potent oligonucleotide sequences for antisense experiments.
Ho SP, Britton DH, Bao Y, Scully MS. Ho SP, et al. Methods Enzymol. 2000;314:168-83. doi: 10.1016/s0076-6879(99)14102-8. Methods Enzymol. 2000. PMID: 10565012 - Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT, Parkinson DR. Ho PT, et al. Semin Oncol. 1997 Apr;24(2):187-202. Semin Oncol. 1997. PMID: 9129689 Review. - Animal models of antisense oligonucleotides: lessons for use in humans.
Plenat F. Plenat F. Mol Med Today. 1996 Jun;2(6):250-7. doi: 10.1016/1357-4310(96)88806-x. Mol Med Today. 1996. PMID: 8796898 Review. - [Antisense oligonucleotide inhibition of coxsackievirus B3 gene expression in HeLa cells and dose-response experiments].
Liu ZW, Sun HM, Xiao ZH, Qiu N, Zhang T, Zhao JM. Liu ZW, et al. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004 Mar;18(1):62-5. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004. PMID: 15340530 Chinese.
Cited by
- Peptide-substituted oligonucleotide synthesis and non-toxic, passive cell delivery.
Shang S, Monfregola L, Caruthers MH. Shang S, et al. Signal Transduct Target Ther. 2016 Oct 21;1:16019. doi: 10.1038/sigtrans.2016.19. eCollection 2016. Signal Transduct Target Ther. 2016. PMID: 29263901 Free PMC article. - Dendritic alpha,epsilon-poly(L-lysine)s as delivery agents for antisense oligonucleotides.
Eom KD, Park SM, Tran HD, Kim MS, Yu RN, Yoo H. Eom KD, et al. Pharm Res. 2007 Aug;24(8):1581-9. doi: 10.1007/s11095-006-9231-y. Epub 2007 Mar 21. Pharm Res. 2007. PMID: 17373579 - Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model.
Pitkänen L, Pelkonen J, Ruponen M, Rönkkö S, Urtti A. Pitkänen L, et al. AAPS J. 2004 Oct 7;6(3):e25. doi: 10.1208/aapsj060325. AAPS J. 2004. PMID: 15760110 Free PMC article. - Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
Deere J, Iversen P, Geller BL. Deere J, et al. Antimicrob Agents Chemother. 2005 Jan;49(1):249-55. doi: 10.1128/AAC.49.1.249-255.2005. Antimicrob Agents Chemother. 2005. PMID: 15616302 Free PMC article. - Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Astriab-Fisher A, et al. Pharm Res. 2002 Jun;19(6):744-54. doi: 10.1023/a:1016136328329. Pharm Res. 2002. PMID: 12134943
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources